Brokers Issue Forecasts for Humacyte FY2026 Earnings

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Humacyte in a report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the company will earn ($0.49) per share for the year. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share.

HUMA has been the subject of several other research reports. Benchmark decreased their price objective on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. HC Wainwright started coverage on shares of Humacyte in a report on Wednesday, May 14th. They set a "buy" rating and a $4.00 target price for the company. D. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research note on Monday. Finally, Wall Street Zen raised shares of Humacyte from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Humacyte presently has a consensus rating of "Moderate Buy" and an average target price of $11.71.

Humacyte Stock Down 1.7%

Shares of Humacyte stock traded down $0.04 on Tuesday, reaching $2.37. 2,720,709 shares of the stock were exchanged, compared to its average volume of 3,856,671. The business has a 50 day moving average price of $1.91 and a two-hundred day moving average price of $3.16. The firm has a market capitalization of $367.63 million, a price-to-earnings ratio of -1.77 and a beta of 2.00. Humacyte has a twelve month low of $1.15 and a twelve month high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Vontobel Holding Ltd. purchased a new stake in Humacyte during the 4th quarter worth approximately $50,000. Rhumbline Advisers lifted its position in shares of Humacyte by 4.6% in the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company's stock valued at $578,000 after acquiring an additional 5,005 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new stake in shares of Humacyte in the fourth quarter worth approximately $130,000. Private Advisor Group LLC increased its position in shares of Humacyte by 60.7% during the fourth quarter. Private Advisor Group LLC now owns 599,700 shares of the company's stock worth $3,028,000 after purchasing an additional 226,590 shares in the last quarter. Finally, Rowlandmiller & PARTNERS.ADV purchased a new stake in shares of Humacyte during the fourth quarter worth approximately $159,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Insider Transactions at Humacyte

In related news, CFO Dale A. Sander acquired 20,000 shares of the firm's stock in a transaction on Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This trade represents a 97.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kathleen Sebelius bought 50,000 shares of the company's stock in a transaction dated Tuesday, April 8th. The stock was bought at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now owns 91,207 shares of the company's stock, valued at approximately $120,393.24. This trade represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 83,993 shares of company stock valued at $118,224 in the last three months. 5.10% of the stock is currently owned by company insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.